Our Objectives

  • Improve access to clinical trials for cancer patients
  • Expand the opportunity for patients to benefit from cutting edge treatments
  • Improve access to precision medicine
  • Improve the cancer patient experience and outcomes
  • Facilitate cancer research so that new drugs and therapies come online faster
Meet Our Board Members
  • “Essentially EVERY advance in cancer therapy has been dependent on the conduct of well-designed clinical trials. It is hard to overstate the importance of increased partnership between patients and their physicians which will allow increased participation in clinical trials, so that the pace of progress in reducing the burden of cancer can be accelerated.” Donald Trump, MD, FACP, FASCO
    CEO Emeritus, Inova Schar Cancer Institute
    Co-Director of the Breast Cancer Program
  • “It’s really important for individuals to keep an open mind about what clinical trials might be available and to talk about that with their physicians. Today’s treatment standards are based on yesterday’s clinical trials.” Vered Stearns, M.D.
    Co-Director of the Breast Cancer Program
  • “The importance of clinical trials can not be overstated. Researchers and clinicians should work together to bring clinical trials to the bedside so patients can avail and benefit from evolving technology and new drugs.” Jeanny B. Aragon-Ching, M.D.
    ACT Board Member, Co-Director of the Breast Cancer Program at Inova Schar Cancer Institute / Inova Fairfax Hospital